Singapore markets open in 2 hours 45 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.5000+0.0600 (+1.35%)
At close: 04:00PM EDT
4.4700 -0.03 (-0.67%)
After hours: 05:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.10B
Enterprise value 929.95M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)3.55k
Price/book (mrq)1.90
Enterprise value/revenue 3.91k
Enterprise value/EBITDA -2.30

Trading information

Stock price history

Beta (5Y monthly) 0.09
52-week change 3-56.64%
S&P500 52-week change 314.91%
52-week high 310.4100
52-week low 34.3750
50-day moving average 36.4288
200-day moving average 36.8539

Share statistics

Avg vol (3-month) 36.2M
Avg vol (10-day) 314.76M
Shares outstanding 5247.78M
Implied shares outstanding 6247.78M
Float 8209.83M
% held by insiders 10.33%
% held by institutions 191.40%
Shares short (14 Sept 2023) 430.51M
Short ratio (14 Sept 2023) 44.52
Short % of float (14 Sept 2023) 413.43%
Short % of shares outstanding (14 Sept 2023) 412.31%
Shares short (prior month 14 Aug 2023) 427.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 325 Sept 2013

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 0.00%
Operating margin (ttm)-179,988.66%

Management effectiveness

Return on assets (ttm)-39.14%
Return on equity (ttm)-79.68%

Income statement

Revenue (ttm)238k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -417.38M
Net income avi to common (ttm)-418.84M
Diluted EPS (ttm)-2.0600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)250.89M
Total cash per share (mrq)1.01
Total debt (mrq)80.71M
Total debt/equity (mrq)13.95%
Current ratio (mrq)3.10
Book value per share (mrq)2.58

Cash flow statement

Operating cash flow (ttm)-335.09M
Levered free cash flow (ttm)-187.97M